Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple ...

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...

Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

Both CAR-Ts are currently approved as fifth-line or later therapies for multiple myeloma, making them an option for around 5,000 patients out of an estimated 32,000 total cases per year in the US.

The future of multiple myeloma treatment is personalised, but collaboration is essential to deliver it. Learn about the latest advancements and how working together can improve outcomes for patients.

The ‘multiple myeloma-like’ genomic score identifies somatic mutations that are more commonly found in active forms of multiple myeloma. In patients with a precursor stage of multiple myeloma ...

Background: Multiple myeloma (MM) is the second most common hematological malignancy that still lacks effective clinical treatments. In particular, MM with central nervous system (CNS) invasion occurs ...